Post Partum Depression (Maternal Depression / Postnatal Depression) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Post Partum Depression (Maternal Depression / Postnatal Depression) – Drugs In Development, 2024 report and make more profitable business decisions.
Post Partum Depression also known as maternal depression and postnatal depression is a medical condition occurs during the pregnancy or after giving the birth (post-partum). Most common condition is prevalent in 1 in 7 women. Many factors like anxiety during the trimester, psychological factors, social support, lifestyle changes, and hormonal changes can cause this condition. Most of the cases are left untreated because of the stigmas attached to it. Persistent feelings of sadness, fatigue, lack of contact with people, loss of appetite, sleep disturbances, and frightening thoughts are some common symptoms. Cognitive behavioral therapy and anti-depressants are treatment strategies. Selective Serotonin reuptake inhibitors (SSRIs) are the first-choice antidepressants.
The Post Partum Depression (Maternal Depression / Postnatal Depression) drugs in development market research report provide comprehensive information on the therapeutics under development for Post Partum Depression (Maternal Depression / Postnatal Depression), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post Partum Depression (Maternal Depression / Postnatal Depression) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Post Partum Depression (Maternal Depression / Postnatal Depression) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 13 molecules, with 13 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Post Partum Depression (Maternal Depression / Postnatal Depression) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Post Partum Depression (Maternal Depression / Postnatal Depression) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Post Partum Depression (Maternal Depression / Postnatal Depression) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Bio-Pharm Solutions Co LtdBiogen Inc
Brii Biosciences Ltd
GABA Therapeutics Inc
Gerbera Therapeutics Ltd
GH Research PLC
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Lipocine Inc
Nanjing Minova Pharmaceutical Technology Co Ltd
Puretech Health Plc
Reunion Neuroscience Inc
Table of Contents
Table
Figures
Frequently asked questions